VectivBio Holding AG (VECT)

Market Cap	492.49M
Revenue (ttm)	n/a
Net Income (ttm)	-87.01M
Shares Out	36.64M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,811
Open	7.79
Previous Close	7.85
Day's Range	7.75 - 7.85
52-Week Range	2.92 - 9.29
Beta	n/a
Analysts	Buy
Price Target	23.46 (+200.8%)
Earnings Date	n/a

About VECT

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, wh...

• Industry: Biotechnology
• IPO Date: Apr 9, 2021
• Employees: 2,021
• Stock Exchange: NASDAQ
• Ticker Symbol: VECT

Analyst Forecast

According to 11 analysts, the average rating for VECT stock is "Buy." The 12-month stock price forecast is 23.46, which is an increase of 200.77% from the latest price.

Price Target

$23.46

(200.77% upside)

Analyst Consensus: Buy